Hodgkin disease, stage I through III A: treatment results at the Zurich University Hospital from 1974 to 1985 and current procedures
Glanzmann, C.; Strebel, U.; Seelentag, W.
Schweizerische Rundschau für Medizin Praxis 78(19): 541-550
1989
ISSN/ISBN: 1013-2058 PMID: 2662326 Document Number: 345406
1974 to 1985, 148 patients with M. Hodgkin I to III A have been treated at the University Hospital Zurich with radiotherapy or radiotherapy and chemotherapy. Ten year survival rates (recurrence free) are: all patients 88% (67%); all with primary radiotherapy 88% (58%); PS I A/II A and radiotherapy 94% (63%); PS III A and primary radiotherapy 78% (56%); patients with recurrence after primary radiotherapy 69% (73%). four cases of acute leukaemia, one case of pancytopenia and sepsis and one case with a myeloproliferative syndrome. Cumulative frequency of leukaemia after ten years is about 7%. Three patients suffered from secondary solid neoplasia. 94% of all living patients are free of symptoms and are working 100%. Based on Ann-Arbor stage, number and volume of involved regions, age, histology, general symptoms and the sedimentation rate, patients with M. Hodgkin CS I to III A can be subdivided in three groups with the following risks of recurrence after primary irradiation without staging laparotomy and splenectomy: a favourable group with a recurrence risk of about 20%. For these patients, primary radiotherapy after clinical staging is an acceptable therapy. In a second group with a high recurrence risk of greater than 50% after irradiation, primary chemotherapy is indicated, usually with additional irradiation of the main tumour manifestations. In a third group with a medium recurrence risk, laparotomy may be further indicated.